We hypothesized that p300 is associated with resistance to DNA-damaging chemotherapy and that targeting p300 can enhance the cytotoxicity of such chemotherapeutic agents in pancreatic cancer. The gene discussed is EP300; the disease is familial pancreatic carcinoma.